Avadel Pharmaceuticals plc (AVDL)


-0.12 (-4.94%)
Symbol AVDL
Price $2.31
Beta 1.170
Volume Avg. 3.97M
Market Cap 136.378M
Shares () -
52 Week Range 1.05-11.59
1y Target Est -
DCF Unlevered AVDL DCF ->
DCF Levered AVDL LDCF ->
ROE -102.82% Strong Sell
ROA -40.84% Strong Sell
Operating Margin -
Debt / Equity 300.36% Strong Buy
P/E -
P/B 2.46 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest AVDL news

Mr. Gregory Divis
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.